Diabetes

Lupin signs licensing pact with Galenicum Health for injectable Semaglutide

Drug maker Lupin on Wednesday said its subsidiary, Lupin Atlantis Holdings SA (LAHSA), has inked a licence and supply agreement with Galenicum Health for diabetes and weight management medication. Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing, and supply, while Lupin will handle regulatory submissions, approvals, and the commercialisation and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia, and Latin America, the Mumbai-based drug maker said in a statement. "Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy," said Fabrice Egros, President, Corporate ...

Weight regain after weight loss drugs is common; here's how to prevent it

Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term

Is liposomal berberine the new weight-loss fix or just online hype?

Promoted as a natural shortcut to fat loss, liposomal berberine is drawing caution from doctors over safety, drug interactions and misleading comparisons with Ozempic

India faces second highest economic burden due to diabetes: Study

India faces the second highest economic burden due to diabetes of USD 11.4 trillion -- the United States bears the highest costs at USD 16.5 trillion, and China the third at USD 11 trillion, a new study has estimated. Researchers, including those from the International Institute for Applied Systems Analysis and the Vienna University of Economics and Business in Austria, calculated the economic impact of diabetes across 204 countries from 2020 to 2050. Global costs amount to around USD 10 trillion, excluding informal care provided by family members -- about 0.2 per cent of the world's annual gross domestic product (GDP), findings published in the journal Nature Medicine show. Factoring in informal care amounts to up to USD 152 trillion, or 1.7 per cent of the world's yearly GDP, the study estimates. "Caregivers often drop out of the labour market, at least partially, which creates additional economic costs," author Klaus Prettner, professor of macroeconomics and digitalisation at th

HC seeks Novo's response on Natco Pharma plea to revoke semaglutide patent

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

How type 2 diabetes physically alters the heart and drives failure

A new human heart study shows type 2 diabetes does not just raise cardiac risk but physically alters heart muscle, energy use and structure, helping explain why heart failure is so common in diabetes

Diabetes-related inflammation may harm male fertility, study suggests

Researchers analysing decades of data report that diabetes, especially type 2, is linked to impaired male fertility, driven largely by inflammatory processes in the body

Scientists discover rare new type of diabetes affecting newborns worldwide

Researchers have identified a previously unknown genetic form of neonatal diabetes that begins within weeks of birth and also disrupts brain development, leading to microcephaly and epileptic seizures

Cipla rolls out Afrezza inhaled insulin in India after CDSCO approval

Cipla has launched Afrezza, an inhaled rapid-acting insulin for adults with diabetes, after CDSCO approval, and plans an awareness drive on insulin adherence

Mounjaro and the brain: Why cravings fade at first, then return later

A rare brain-recording study found tirzepatide briefly muted activity linked to 'food noise'; months later the signals and intrusive thoughts returned, hinting at limits to its effect

Biocon launches drugs for diabetes and obesity treatment in Netherlands

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Why erectile dysfunction may be an early alarm for diabetes, heart disease

Far from being only a sexual concern, erectile dysfunction may be the body's first alarm bell for hidden cardiometabolic disease, prompting earlier diagnosis of diabetes, hypertension

Novo Nordisk set to launch diabetes drug Ozempic in India this month

Ozempic, a once-weekly injectable approved by the US Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight los

Diabetes and oral health are linked: Here's what you need to know

Diabetes care routinely focuses on the heart, feet, eyes, liver and kidneys. The mouth, however, is frequently overlooked, even though oral health both affects and is affected by diabetes

How poor diabetes management increases complications in people with HIV

Experts warn that poor sugar control pushes HIV-related health risks higher, leading to faster progression of heart, kidney and nerve problems

How routine eye checkups can reveal disease years before symptoms emerge

From heart health to neurological decline, the eye's tiny vessels and nerves can reveal silent disease changes long before patients notice anything is wrong

Insulin without needles: Can a simple skin cream replace injections?

A breakthrough Nature study shows that a specially engineered polymer can carry insulin through the skin, lowering blood sugar in animals and raising hopes of a painless, needle-free diabetes treatmen

India's metabolic crisis deepens as young adults face diabetes surge

Diabetes is increasingly becoming a major global health concern, with an estimated 589 million adults currently living with the condition and the number expected to rise to 853 million by 2050

How long sitting spikes your blood sugar, even if you work out daily

Doctors warn that long, uninterrupted sitting may worsen blood sugar, raise inflammation and weaken diabetes management, particularly among desk-based professionals

Only 27% of Mumbaikars aware of sugar risks, 15.6% pre-diabetic: BMC

A civic survey in Mumbai has indicated that only 27 per cent of residents are aware of the harmful effects of excessive sugar consumption, while 15.6 per cent are in the pre-diabetic stage. The Brihanmumbai Municipal Corporation (BMC) has appealed to residents to reduce sugar consumption and read food labels carefully before consuming processed foods. BMC Commissioner and Administrator Bhushan Gagrani has appealed to citizens to participate in the 'Healthy Campus Initiative', launched on the occasion of World Diabetes Day on November 14, to encourage healthier dietary and lifestyle practices. According to the World Health Organisation's Global Burden of Disease Studies, one in three people worldwide suffers from non-communicable diseases (NCDs) such as diabetes and hypertension, a civic release said. The BMC screened 5,59,751 individuals for diabetes and hypertension across its health institutions from August 2022 to October 2025, it said. As per the release, a civic survey has ..